EP0230298A2 - Stable solid preparation of thiol or thiol ester derivatives - Google Patents

Stable solid preparation of thiol or thiol ester derivatives Download PDF

Info

Publication number
EP0230298A2
EP0230298A2 EP87100656A EP87100656A EP0230298A2 EP 0230298 A2 EP0230298 A2 EP 0230298A2 EP 87100656 A EP87100656 A EP 87100656A EP 87100656 A EP87100656 A EP 87100656A EP 0230298 A2 EP0230298 A2 EP 0230298A2
Authority
EP
European Patent Office
Prior art keywords
parts
thiol ester
ester derivative
mixed
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP87100656A
Other languages
German (de)
French (fr)
Other versions
EP0230298B1 (en
EP0230298A3 (en
Inventor
Heiji Ikushima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Priority to AT87100656T priority Critical patent/ATE58833T1/en
Publication of EP0230298A2 publication Critical patent/EP0230298A2/en
Publication of EP0230298A3 publication Critical patent/EP0230298A3/en
Application granted granted Critical
Publication of EP0230298B1 publication Critical patent/EP0230298B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Definitions

  • the present invention relates to a stable solid preparation of thiol ester derivative that will be very useful as a drug. More particularly, the present invention pertains to a stable solid thiol ester derivative preparation which contains as active ingredients a thiol ester derivative of the formula [I]: (where R is hydrogen or an acyl group; A is a residue of glycine, sacrosine or a-D-amino acid, the a-carbonyl group of which forms a thiol ester linkage with the sulfur atom; n is an integer 0 or 1; and B is a hydroxyl group or an amino acid residue) or a salt thereof, a water-soluble wax which is solid at ordinary temperatures, and sodium carboxymethyl starch (CMS-Na) and/or a monovalent electrolyte.
  • R is hydrogen or an acyl group
  • A is a residue of glycine, sacrosine or a-D-amino acid, the a-carbonyl group of which forms
  • the present invention relates to a stable solid thiol ester derivative preparation which contains as active ingredients a thiol ester derivative of the formula [I]:
  • R is hydrogen, or an acyl group which is selected from the group consisting of an acetyl, butanecarbonyl, cyclopropanecarbonyl, cyclohexanecarbonyl and adamantane- carbonyl groups and which is linked to an a-amino group of an amino acid of A
  • A is a residue of glycine, sacrosine or a-D-amino acid, the a-carbonyl group of which forms a thiol ester linkage with the sulfur atom
  • n is an integer 0 or 1
  • B is a hydroxyl group or an amino acid residue
  • a salt thereof a water-soluble wax which is solid at ordinary temperatures, or sodium carboxymethyl starch and/or a monovalent electrolyte.
  • Thiol ester derivatives represented by the formula [I] have an action suppressing angiotensin converting enzyme.
  • Thiol ester derivatives which are in a solid state are sensitive to moisture. Therefore, when formulated by an ordinary method, they are affected by water contained in an excipient and by adsorption of moisture in the air, causing decomposition or oxidation, and thus resulting in deterioration of their properties. In order to stabilize such unstable thiol ester derivatives, it is necessary to formulate preparations having water in excipients removed as much as possible and to put them in glass bottles or package them in metallic moistureproof materials. Alternatively, in the case of preparations formulated by an ordinary method, they must be protected by, for example, enclosing a desiccant in their packaging. In these practices, the dehumidification required in formulation and rises in the packaging cost both increase the financial burden on the manufacturer, and it is_also troublesome for users to handle and use such preparations.
  • the present inventor therefore made various studies in order to obtain a stable solid preparation of thiol ester derivative, and found that a considerably stable solid preparation can be obtained by blending certain additives such as an appropriate wax, a monovalent electrolyte, etc.
  • the present invention has been accomplished on the basis of this finding.
  • the present invention provides a stable solid thiol ester derivative preparation obtained in such a manner that one or more water-soluble waxes which are solid at ordinary temperatures are added to and mixed with a thiol ester derivative in an amount from 1% to 50%, preferably from 5% to 30%, and this mixture is heated to a temperature above the melting point of the water-soluble wax(es) to allow the wax to become flowable, and is then stirred so that the wax component is coated on and aggregated with the thiol ester derivative.
  • the aggregate is cooled to obtain a granulated substance, to which is added sodium carboxymethyl starch and/or a monovalent electrolyte in an amount of 0.01% or more, preferably from 0.1% to 20% with respect to the thiol ester derivative.
  • Typical thiol ester derivatives which may be employed in the present invention include N-[3-(N-cyclohexanecarbonyl- 'D-alanylthio)-2-D-methylpropanoyl]-L-proline (hereinafter referred to as "compound 1”), N-[3-(N-pivaloyl-D-alanylthio)-2-D-methylpropano ⁇ l]-L-proline (hereinafter referred to as "compound 2”), D-3-mercapto-2-methylpropanoyl-L-proline (hereinafter referred to as "compound 3”) and N-[3-(N-cyclopropanecarbonyl-D-alanylthio)-2-D-methylpropanoyl]-L-proline (hereinafter referred to as "compound 4"), and also include various salts of these compounds, such as potassium, sodium and lysine salts.
  • compound 1 N-[3-(N-cycl
  • Water-soluble waxes which are solid at ordinary temperatures and which may be employed in the present invention are any waxes having a melting point of 35°C or higher, preferably from 37°C to 70 0 C. Examples include polyethylene glycols, polyethylene propylene glycols, polyethylene nonyl phenol ethers and polyoxyethylene higher alcohol esters. These waxes may be employed alone or mixed together as desired.
  • Heat granulation methods which may be suitably employed in the present invention include generally known granulating methods such as melt granulation, spray granulation, granulation in which a melt is cooled and powdered, fluidized bed granulation and heat granulation by stirring. The feature of these methods resides in that a wax is melted or softened at high temperature, and the ingredients are aggregated by stirring or rolling and then cooled to obtain a granulated substance.
  • CMS-Na which is employed in the present invention is generally used as a food additive by the name of carboxymethyl starch.
  • Examples of monovalent electrolytes which may be employed in the present invention include sodium chloride, potassium chloride, sodium bromide, lithium chloride and sodium nitrate, and these electrolytes may be mixed together when added to the selected thiol ester derivative.
  • Excipients which may appropriately be employed in formulation include lactose, corn starch, potato starch, crystalline cellulose, mannitol, calcium citrate and calcium hydrogenphosphate.
  • Solid preparations obtained in accordance with the present invention have excellent stability.
  • the calcium salt of the compound 2 was processed in the same way as in Example 1 to obtain tablets.
  • the compound 4 was processed in the same way as in Example 1 to obtain tablets.
  • Example 1 Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 1, and tablets were obtained in the same way as in Example 1.
  • a powder mixture obtained in the same way as in Comparative Example 2 was charged into hard capsules by an ordinary method to obtain capsulated preparations.
  • Example 5 Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 5, and tablets were obtained in the same way as in Example 5.
  • Example 6 Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 6, and tablets were obtained in the same way as in Example 6.
  • Example 7 Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 7, and tablets were obtained in the same way as in Example 7.
  • Example 11 Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 11, and tablets were obtained in the same way as in Example 11.
  • Example 12 Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 12, and tablets were obtained in the same way as in Example 12.
  • Example 13 Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 13, and tablets were obtained in the same way as in Example 13.
  • Example 7 Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 7, and the mixture was then charged into hard capsules by an ordinary method to obtain capsulated preparations.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A stable solid thiol ester derivative preparation which contains as active ingredients a thiol ester derivative or a saltthere- of, a water-soluble wax which is solid at ordinary temperatures, and sodium carboxymethyl starch and/or a monovalent electrolyte. Thiol ester derivatives are very useful as drugs but, in a solid state, they are sensitive to moisture. A stable solid preparation of thiol ester derivative is obtained by mixing the above additives and/or a monovalent electrolyte into a thiol ester derivative.

Description

  • The present invention relates to a stable solid preparation of thiol ester derivative that will be very useful as a drug. More particularly, the present invention pertains to a stable solid thiol ester derivative preparation which contains as active ingredients a thiol ester derivative of the formula [I]:
    Figure imgb0001
    (where R is hydrogen or an acyl group; A is a residue of glycine, sacrosine or a-D-amino acid, the a-carbonyl group of which forms a thiol ester linkage with the sulfur atom; n is an integer 0 or 1; and B is a hydroxyl group or an amino acid residue) or a salt thereof, a water-soluble wax which is solid at ordinary temperatures, and sodium carboxymethyl starch (CMS-Na) and/or a monovalent electrolyte. More specifically, the present invention relates to a stable solid thiol ester derivative preparation which contains as active ingredients a thiol ester derivative of the formula [I]:
    Figure imgb0002
    (where R is hydrogen, or an acyl group which is selected from the group consisting of an acetyl, butanecarbonyl, cyclopropanecarbonyl, cyclohexanecarbonyl and adamantane- carbonyl groups and which is linked to an a-amino group of an amino acid of A; A is a residue of glycine, sacrosine or a-D-amino acid, the a-carbonyl group of which forms a thiol ester linkage with the sulfur atom; n is an integer 0 or 1; and B is a hydroxyl group or an amino acid residue) or a salt thereof, a water-soluble wax which is solid at ordinary temperatures, or sodium carboxymethyl starch and/or a monovalent electrolyte.
  • Thiol ester derivatives represented by the formula [I] have an action suppressing angiotensin converting enzyme.
  • Thiol ester derivatives which are in a solid state are sensitive to moisture. Therefore, when formulated by an ordinary method, they are affected by water contained in an excipient and by adsorption of moisture in the air, causing decomposition or oxidation, and thus resulting in deterioration of their properties. In order to stabilize such unstable thiol ester derivatives, it is necessary to formulate preparations having water in excipients removed as much as possible and to put them in glass bottles or package them in metallic moistureproof materials. Alternatively, in the case of preparations formulated by an ordinary method, they must be protected by, for example, enclosing a desiccant in their packaging. In these practices, the dehumidification required in formulation and rises in the packaging cost both increase the financial burden on the manufacturer, and it is_also troublesome for users to handle and use such preparations.
  • The present inventor therefore made various studies in order to obtain a stable solid preparation of thiol ester derivative, and found that a considerably stable solid preparation can be obtained by blending certain additives such as an appropriate wax, a monovalent electrolyte, etc. The present invention has been accomplished on the basis of this finding.
  • Thus, the present invention provides a stable solid thiol ester derivative preparation obtained in such a manner that one or more water-soluble waxes which are solid at ordinary temperatures are added to and mixed with a thiol ester derivative in an amount from 1% to 50%, preferably from 5% to 30%, and this mixture is heated to a temperature above the melting point of the water-soluble wax(es) to allow the wax to become flowable, and is then stirred so that the wax component is coated on and aggregated with the thiol ester derivative. Then, the aggregate is cooled to obtain a granulated substance, to which is added sodium carboxymethyl starch and/or a monovalent electrolyte in an amount of 0.01% or more, preferably from 0.1% to 20% with respect to the thiol ester derivative.
  • Typical thiol ester derivatives which may be employed in the present invention include N-[3-(N-cyclohexanecarbonyl- 'D-alanylthio)-2-D-methylpropanoyl]-L-proline (hereinafter referred to as "compound 1"), N-[3-(N-pivaloyl-D-alanylthio)-2-D-methylpropanoψl]-L-proline (hereinafter referred to as "compound 2"), D-3-mercapto-2-methylpropanoyl-L-proline (hereinafter referred to as "compound 3") and N-[3-(N-cyclopropanecarbonyl-D-alanylthio)-2-D-methylpropanoyl]-L-proline (hereinafter referred to as "compound 4"), and also include various salts of these compounds, such as potassium, sodium and lysine salts.
  • Water-soluble waxes which are solid at ordinary temperatures and which may be employed in the present invention are any waxes having a melting point of 35°C or higher, preferably from 37°C to 700C. Examples include polyethylene glycols, polyethylene propylene glycols, polyethylene nonyl phenol ethers and polyoxyethylene higher alcohol esters. These waxes may be employed alone or mixed together as desired. Heat granulation methods which may be suitably employed in the present invention include generally known granulating methods such as melt granulation, spray granulation, granulation in which a melt is cooled and powdered, fluidized bed granulation and heat granulation by stirring. The feature of these methods resides in that a wax is melted or softened at high temperature, and the ingredients are aggregated by stirring or rolling and then cooled to obtain a granulated substance.
  • CMS-Na which is employed in the present invention is generally used as a food additive by the name of carboxymethyl starch.
  • Examples of monovalent electrolytes which may be employed in the present invention include sodium chloride, potassium chloride, sodium bromide, lithium chloride and sodium nitrate, and these electrolytes may be mixed together when added to the selected thiol ester derivative.
  • Excipients which may appropriately be employed in formulation include lactose, corn starch, potato starch, crystalline cellulose, mannitol, calcium citrate and calcium hydrogenphosphate.
  • Solid preparations obtained in accordance with the present invention have excellent stability.
  • The following examples are provided for the purpose of further illustrating the present invention but are not to be construed as limiting. It should be noted that "parts" in the following examples denote parts by weight.
  • Example 1
  • Twenty parts of polyethylene glycol-6000 was added to and mixed with 80 parts of crystalline powder of the calcium salt of compound 1, and the.mixture was then granulated by heating to obtain a granulated substance. Ten parts of CMS-Na was added to and mixed with 90 parts of the obtained granulated substance, and the mixture was then subjected to an ordinary tablet making process to obtain tablets.
  • Example 2
  • Five parts of CMS-Na was added to and mixed with 95 parts of a granulated substance obtained from the compound 3 in the same way as in Example 1, and the mixture was then subjected to an ordinary tablet making process to obtain tablets.
  • Example 3
  • Twenty parts of CMS-Na was added to and mixed with 80 parts of a granulated substance obtained in the same way as in Example 1, and the mixture was then subjected to an ordinary tablet making process to obtain tablets.
  • Example 4
  • Ten parts of C14S-Na was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 1, and the mixture was then charged into hard capsules by an ordinary method to obtain capsulated preparations.
  • Example 5
  • The calcium salt of the compound 2 was processed in the same way as in Example 1 to obtain tablets.
  • Example 6
  • The compound 4 was processed in the same way as in Example 1 to obtain tablets.
  • 'Example 7
  • Twenty parts of polyethylene glycol-6000 was added to and mixed with 80 parts of crystalline powder of the calcium salt of the compound 1. The mixture was then granulated by heating to obtain a granulated substance. Nine parts of corn starch and one part of sodium chloride were added to and mixed with 90 parts of the obtained granulated substance, and the mixture was then subjected to an ordinary tablet making process to obtain tablets.
  • Example 8
  • Nine parts of corn starch and one part of potassium chloride were added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 7, and the mixture was then subjected to an ordinary tablet making process to obtain tablets.
  • Example 9
  • Nine parts of corn starch and one part of sodium bromide were added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 7, and the mixture was then subjected to an ordinary tablet making process to obtain tablets.
  • Example 10
  • Nine parts of corn starch and one part of sodium nitrate were added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 7, and the mixture was then subjected to an ordinary tablet making process to obtain tablets.
  • Example 11
  • Twenty parts of polyethylene glycol-6000 was added to and mixed with 80 parts of crystalline powder of the calcium salt of compound 3. The mixture was then granulated by heating to obtain a granulated substance, and 9.9 parts of corn starch and 0.1 part of sodium chloride were added to and mixed with 90 parts of the obtained granulated substance. The mixture was then subjected to an ordinary tablet making process to obtain tablets.
  • Example 12
  • Twenty parts of polyethylene polypropylene glycol was added to and mixed with 80 parts of crystalline powder of the calcium salt of compound 2, and the mixture was then granulated by heating to obtain a granulated substance. Nine parts of corn starch and one part of sodium chloride were added to and mixed with 90 parts of the obtained granulated substance, and the mixture was then subjected to an ordinary tablet making process to obtain tablets.
  • Example 13
  • Twenty parts of polyethylene glycol-6000 was added to and mixed with 80 parts of,crystalline powder of the calcium salt of compound 4, and the mixture was then granulated by heating to obtain a granulated substance. Nine parts of microcrystalline cellulose and one part of sodium chloride were added to and mixed with 90 parts of the obtained granu- lated substance, and the mixture was then subjected to an ordinary tablet making process to obtain tablets.
  • Example 14
  • Nine parts of corn starch and one part of potassium chloride were added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 7, and the mixture was then charged into hard capsules by an ordinary method to obtain capsulated preparations.
  • Example 15
  • Twenty parts of polyethylene glycol-6000 was added to and mixed with 80 parts of crystalline powder of the calcium salt of compound 1. The mixture was then granulated by heating to obtain a granulated substance, and 9.5 parts of CMS-Na and 0.5 parts of sodium chloride were added to and mixed with 90 parts of the obtained granulated substance. The mixture was then subjected to an ordinary tablet making process to obtain tablets.
  • Example 16
  • Nineteen parts of mannitol; 0.5 parts of sodium chloride and 0.5 parts of potassium chloride were added to and mixed with 80 parts of a granulated substance obtained in the same way as in Example 15, and the mixture was then subjected to an ordinary tablet making process to obtain tablets.
  • Comparative Example 1
  • Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 1, and tablets were obtained in the same way as in Example 1.
  • Comparative Example 2
  • Fifty parts of lactose and 30 parts of microcrystalline cellulose were added to and mixed with 20 parts of calcium salt of the compound 1, and the mixture was then subjected to an ordinary tablet making process to obtain tablets.
  • Comparative Example 3
  • A powder mixture obtained in the same way as in Comparative Example 2 was charged into hard capsules by an ordinary method to obtain capsulated preparations.
  • Comparative Example 4
  • Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 5, and tablets were obtained in the same way as in Example 5.
  • Comparative Example 5
  • Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 6, and tablets were obtained in the same way as in Example 6.
  • Comparative Example 6
  • Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 7, and tablets were obtained in the same way as in Example 7.
  • Comparative Example 7
  • Forty parts of lactose and 20 parts of microcrystalline cellulose were added to and mixed with 40 parts of the calcium salt of compound 1, and the mixture was then subjected to an ordinary tablet making process to obtain tablets.
  • Comparative Example 8
  • Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 11, and tablets were obtained in the same way as in Example 11.
  • Comparative Example 9
  • Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 12, and tablets were obtained in the same way as in Example 12.
  • Comparative Example 10
  • Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 13, and tablets were obtained in the same way as in Example 13.
  • Comparative Example 11
  • Ten parts of corn starch was added to and mixed with 90 parts of a granulated substance obtained in the same way as in Example 7, and the mixture was then charged into hard capsules by an ordinary method to obtain capsulated preparations.
  • Experimental Example
  • A stability test was carried out on the preparation samples shown in the Examples and Comparative Examples under the following conditions. Six grams of each sample was put in a glass bottle and, with the bottle opened, it was stored in a desiccator at 50oC - 75% RH (relative humidity). After 30 days or 60 days had passed, the residual amount of the principal ingredient in the sample was measured by highspeed liquid chromatography. The results are shown in Tables 1 and 2 below.
    Figure imgb0003
    Figure imgb0004

Claims (2)

1. A stable solid thiol ester derivative preparation which contains as active ingredients a thiol ester derivative of the formula [I]:
Figure imgb0005
(where R is hydrogen or an acyl group; A is a residue of glycine, sacrosine or a-D-amino acid, the a-carbonyl group of which forms a thiol ester linkage with the sulfur atom; n is an integer 0 or 1; and B is a hydroxyl group or an amino acid residue) or a salt thereof, a water-soluble wax which is solid at ordinary temperatures, and sodium carboxymethyl starch and/or a monovalent electrolyte.
2. A stable solid thiol ester derivative preparation according to Claim 1, which contains as active ingredients a thiol ester derivative of the formula [I]:
Figure imgb0006
(where R is hydrogen, or an acyl group which is selected from the group consisting of an acetyl, butanecarbonyl, cyclopropanecarbonyl, cyclohexanecarbonyl and4adamantane- carbonyl groups and which is linked to an a-amino group of an amino acid of A; A is a residue of glycine, sacrosine or a-D-amino acid, the a-carbonyl group of which forms a thiol ester linkage with the sulfur atom; n is an integer 0 or 1; and B is a hydroxyl group or an amino acid) or a salt thereof, a water-soluble wax which is solid at ordinary temperatures, and sodium carboxymethyl starch and/or a monovalent electrolyte.
EP87100656A 1986-01-21 1987-01-20 Stable solid preparation of thiol or thiol ester derivatives Expired - Lifetime EP0230298B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT87100656T ATE58833T1 (en) 1986-01-21 1987-01-20 STABLE SOLID PREPARATION OF THIOL OR THIOLESTER DERIVATIVES.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP1070686 1986-01-21
JP10706/86 1986-01-21
JP125901/86 1986-06-02
JP12590186 1986-06-02

Publications (3)

Publication Number Publication Date
EP0230298A2 true EP0230298A2 (en) 1987-07-29
EP0230298A3 EP0230298A3 (en) 1988-01-20
EP0230298B1 EP0230298B1 (en) 1990-12-05

Family

ID=26346027

Family Applications (1)

Application Number Title Priority Date Filing Date
EP87100656A Expired - Lifetime EP0230298B1 (en) 1986-01-21 1987-01-20 Stable solid preparation of thiol or thiol ester derivatives

Country Status (10)

Country Link
US (1) US4783334A (en)
EP (1) EP0230298B1 (en)
KR (1) KR870007114A (en)
CA (1) CA1285487C (en)
DE (1) DE3766502D1 (en)
DK (1) DK29087A (en)
ES (1) ES2018787B3 (en)
FI (1) FI84883C (en)
GR (1) GR3001175T3 (en)
NO (1) NO870233L (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0546358A2 (en) * 1991-11-20 1993-06-16 Takeda Chemical Industries, Ltd. Pharmaceutical compositions with angiotensin-II-antagonistic activity

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2355743A1 (en) * 1972-10-31 1975-05-22 Hoechst Ag NEW FORMS OF PREPARATION OF N-SQUARE CLAMP TO 2- (5-CHLORO-2-METHOXYBENZAMIDO) -AETHYL SQUARE CLAMP TO -PHENYLSULFONYL-N'-CYCLOHEXYL UREA AND ITS SALT AND MANUFACTURING METHOD FOR THEIR PRODUCTION
AU507575B2 (en) * 1975-11-17 1980-02-21 Sandoz Ltd. Griseofulvin tablet
US4283407A (en) * 1977-09-28 1981-08-11 Science Union Et Cie Thiopropionamides, and the pharmaceutical compositions
FR2508040A1 (en) * 1981-06-19 1982-12-24 Chugai Pharmaceutical Co Ltd PROLINE DERIVATIVES, PROCESS FOR PREPARING THEM AND MEDICAMENT CONTAINING SAME
EP0072868A1 (en) * 1981-02-28 1983-03-02 Santen Pharmaceutical Co., Ltd. Cyclodextrin clathrate compounds of sulfur-containing compounds
CH656535A5 (en) * 1986-01-24 1986-07-15 Spirig Ag Process for the production of stable pharmaceutical tablets which disintegrate rapidly in water

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2355743A1 (en) * 1972-10-31 1975-05-22 Hoechst Ag NEW FORMS OF PREPARATION OF N-SQUARE CLAMP TO 2- (5-CHLORO-2-METHOXYBENZAMIDO) -AETHYL SQUARE CLAMP TO -PHENYLSULFONYL-N'-CYCLOHEXYL UREA AND ITS SALT AND MANUFACTURING METHOD FOR THEIR PRODUCTION
AU507575B2 (en) * 1975-11-17 1980-02-21 Sandoz Ltd. Griseofulvin tablet
US4283407A (en) * 1977-09-28 1981-08-11 Science Union Et Cie Thiopropionamides, and the pharmaceutical compositions
EP0072868A1 (en) * 1981-02-28 1983-03-02 Santen Pharmaceutical Co., Ltd. Cyclodextrin clathrate compounds of sulfur-containing compounds
FR2508040A1 (en) * 1981-06-19 1982-12-24 Chugai Pharmaceutical Co Ltd PROLINE DERIVATIVES, PROCESS FOR PREPARING THEM AND MEDICAMENT CONTAINING SAME
CH656535A5 (en) * 1986-01-24 1986-07-15 Spirig Ag Process for the production of stable pharmaceutical tablets which disintegrate rapidly in water

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0546358A2 (en) * 1991-11-20 1993-06-16 Takeda Chemical Industries, Ltd. Pharmaceutical compositions with angiotensin-II-antagonistic activity
EP0546358A3 (en) * 1991-11-20 1994-03-30 Takeda Chemical Industries Ltd
US5534534A (en) * 1991-11-20 1996-07-09 Takeda Chemical Industries, Ltd. Pharmaceutical compositions for oral use and method of preparing them
EP1468683A2 (en) * 1991-11-20 2004-10-20 Takeda Chemical Industries, Ltd. Pharmaceutical composition for oral use with angiotensin-II-antagonistic activity and method of preparing it
EP1468683A3 (en) * 1991-11-20 2012-06-06 Takeda Pharmaceutical Company Limited Pharmaceutical composition for oral use with angiotensin-II-antagonistic activity and method of preparing it

Also Published As

Publication number Publication date
NO870233D0 (en) 1987-01-20
ES2018787B3 (en) 1991-05-16
FI84883C (en) 1992-02-10
FI84883B (en) 1991-10-31
NO870233L (en) 1987-07-22
DE3766502D1 (en) 1991-01-17
DK29087D0 (en) 1987-01-20
GR3001175T3 (en) 1992-06-30
EP0230298B1 (en) 1990-12-05
FI870248A (en) 1987-07-22
KR870007114A (en) 1987-08-14
DK29087A (en) 1987-07-22
US4783334A (en) 1988-11-08
CA1285487C (en) 1991-07-02
EP0230298A3 (en) 1988-01-20
FI870248A0 (en) 1987-01-21

Similar Documents

Publication Publication Date Title
JP4065321B2 (en) Gelatin capsules with controlled water activity
EP0361680B1 (en) Morphine-containing composition
US5151433A (en) Stabilized medicinal substances, a process for the preparation thereof, and stable medicinal formulations
US3082154A (en) Improved free-flowing coated antimalarial salts in particulate form
JP4621326B2 (en) Teprenone stabilized composition
DK174893B1 (en) Clodronate-containing preparations and processes for their preparation
AU751575B2 (en) Pharmaceutical levothyroxine preparation
CA2011943A1 (en) Compositions for the preparation of dosage-form active vitamins d3 and process for preparing stable dosage-form active vitamins d3 by using the same
EP0264259B1 (en) Stabilized pharmaceutical compositions
US4666919A (en) Stabilized pharmaceutical composition containing an isocarbostyril derivative
AU3932199A (en) Pharmaceutical preparation containing levothyroxine sodium
EP0394022B1 (en) Calcium pantothenate composit
EP0230298B1 (en) Stable solid preparation of thiol or thiol ester derivatives
KR20060071897A (en) HIGH PURITY (7α,17α)-17-HYDROXY-7-METHYL-19-NOR-17-PREGN-5(10)-EN-20-YN-3-ONE AND HIGH PURITY COMPOSITION COMPRISING THE SAME
EP0063884B1 (en) Oxazole derivatives, their preparation and use
EP0159777A1 (en) Stabilized 4-carbamoyl-imidazolium-5-olate
EP1292598B1 (en) Process for drying amoxicillin
JPS6399012A (en) Stable solid agent of thiol ester derivative
KR100686300B1 (en) Hydroxypropylmethylcellulose Capsule Preparation Having Teprenone Encapsulated Therein
JPH0242811B2 (en)
WO2022075436A1 (en) A method of producing thyroid hormone-containing formulation
JPS59157015A (en) Muzolimine-containing drug, use and manufacture
JPS6056974A (en) Cyclic dithiodiacetamide, manufacture and drug
JP2000219639A (en) Pharmaceutical composition
JPH09268127A (en) Solid preparation composition containing vitamin b1 derivative

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE ES FR GB GR IT LI NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE ES FR GB GR IT LI NL SE

17P Request for examination filed

Effective date: 19880308

17Q First examination report despatched

Effective date: 19890626

ITTA It: last paid annual fee
ITF It: translation for a ep patent filed
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19901123

Year of fee payment: 5

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE ES FR GB GR IT LI NL SE

REF Corresponds to:

Ref document number: 58833

Country of ref document: AT

Date of ref document: 19901215

Kind code of ref document: T

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19901219

Year of fee payment: 5

Ref country code: GR

Payment date: 19901219

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19901227

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19901228

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19910107

Year of fee payment: 5

REF Corresponds to:

Ref document number: 3766502

Country of ref document: DE

Date of ref document: 19910117

ET Fr: translation filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 19910118

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19910131

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19910311

Year of fee payment: 5

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19910326

Year of fee payment: 5

REG Reference to a national code

Ref country code: GR

Ref legal event code: FG4A

Free format text: 3001175

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19920120

Ref country code: AT

Effective date: 19920120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19920121

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19920121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Effective date: 19920131

Ref country code: CH

Effective date: 19920131

Ref country code: BE

Effective date: 19920131

BERE Be: lapsed

Owner name: CHUGAI SEIYAKU K.K.

Effective date: 19920131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19920731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19920801

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
REG Reference to a national code

Ref country code: GB

Ref legal event code: PCNP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Effective date: 19920930

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19921001

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

REG Reference to a national code

Ref country code: GR

Ref legal event code: MM2A

Free format text: 3001175

EUG Se: european patent has lapsed

Ref document number: 87100656.5

Effective date: 19920806

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 19990201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050120